Selinexor and Radiation Therapy Trial for DIPG and HGG Shows Promise
A phase I/II trial is evaluating the safety and efficacy of selinexor combined with radiation therapy in children with DIPG and HGG.
Phase I
Oncology / Glioma
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The ongoing trial of selinexor in combination with radiation therapy represents a significant advancement in the treatment of high-risk gliomas, particularly in pediatric patients. Positive outcomes could enhance selinexor's market position and challenge existing therapies in the oncology landscape.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor results from both the Dose-Finding and Efficacy phases for insights on dosing and treatment effectiveness.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.